SAN CLEMENTE, Calif.,
Feb. 22, 2018 /PRNewswire/
-- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of
minimally invasive medical devices to treat obesity and metabolic
diseases, announced today that the Company and its products will be
discussed during the Metabolic and Bariatric Sessions of the
Minimally Invasive Surgery Symposium (MISS) taking place in
Las Vegas from March 6-9, 2018.
Details of the presentations are as follows:
Friday, March 9, 2018:
11:00 AM:
Metablolic/ Bariatric Session V: New
Frontiers
Moderator: John B Dixon, MBBS, PhD,
FRACGP, FRCP, Edin
11:00-11:15 AM
Presentation Title: Gastric Wrapping: The Gastric Vest
Presenter: Jaime Ponce, MD, FACS,
FASMBS
1:00-1:15 PM
Presentation Title: What's New with Gastric Balloons
Presenter: Jaime Ponce, MD, FACS,
FASMBS
For more details on the Minimally Invasive Surgery Symposium,
please visit
https://www.globalacademycme.com/conferences/miss/minimally-invasive-surgery-symposium-miss-overview
About ReShape Lifesciences Inc.
ReShape Lifesciences is a medical device company focused on
technology to treat obesity and metabolic diseases. The
FDA-approved ReShape® Balloon involves a
non-surgical weight loss procedure that uses advanced
interconnected balloon technology designed to take up room in the
stomach to help people with a 30-40 Body Mass Index (BMI), and at
least one co-morbidity, feel full and lose weight. vBloc®
Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like
device called the vBloc System, is designed to help patients with a
BMI of 40-45, or 35-39.9 with a minimum of one related comorbid
condition, eat less and lose weight by intermittently blocking
hunger signals on the vagus nerve. The ReShape Vest™
System is an investigational, minimally invasive, laparoscopically
implanted medical device that wraps around the stomach, emulating
the gastric volume reduction effect of conventional weight-loss
surgery, and is intended to enable rapid weight loss in obese and
morbidly obese patients without permanently changing patient
anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as expect," "plan," "anticipate," "could,"
"may," "intend," "will," "continue," "future," other words of
similar meaning and the use of future dates. These forward-looking
statements are based on the current expectations of our management
and involve known and unknown risks and uncertainties that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others:
risks and uncertainties related to our acquisitions of ReShape
Medical, Inc. and BarioSurg, Inc.; risks related to the U.S. Food
and Drug Administration's announcement to alert health care
providers of unanticipated deaths involving the ReShape Balloon;
our proposed ReShape Vest product may not be successfully developed
and commercialized; our ability to continue as a going concern if
we are unsuccessful in our pursuit of various funding options; our
limited history of operations; our losses since inception and for
the foreseeable future; our limited commercial sales experience;
the competitive industry in which we operate; our ability to
maintain compliance with the Nasdaq continued listing requirements;
our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for our
ReShape Vest and any modifications to our vBloc system or ReShape
Balloon; physician adoption of our products; our ability to obtain
third party coding, coverage or payment levels; ongoing regulatory
compliance; our dependence on third party manufacturers and
suppliers; the successful development of our sales and marketing
capabilities; our ability to raise additional capital when needed;
international commercialization and operation; our ability to
attract and retain management and other personnel and to manage our
growth effectively; potential product liability claims; the cost
and management time of operating a public company; potential
healthcare fraud and abuse claims; healthcare legislative reform;
and our ability to obtain and maintain intellectual property
protection for our technology and products. These and additional
risks and uncertainties are described more fully in the Company's
filings with the Securities and Exchange Commission, particularly
those factors identified as "risk factors" in Exhibit 99.3 of our
current report on Form 8-K filed January 31, 2018. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/reshape-lifesciences-technologies-to-be-featured-at-minimally-invasive-surgery-symposium-300603031.html
SOURCE ReShape Lifesciences Inc.